12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Mekinist trametinib regulatory update

GlaxoSmithKline submitted a pair of sNDAs to expand the labels for melanoma drugs Tafinlar dabrafenib ( GSK2118436) and Mekinist trametinib to include their combination use to treat adults with unresectable or metastatic melanoma with a BRAF V600E or...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >